Integrated Solutions from Research to Commercialisation.
Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.
Our vast range of services include:
Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory.
API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.
Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.
Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.
Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.
Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.
Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.
Almac – Partnering to Advance Human Health™
Mr Gildas Lavenant
Mr Philip Diamond
Mr Philip Berry
Mr Glyn Allsop
Mr Simon LawrenceGalen Ltd
Dr Rob GrundyAlmac Discovery
Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
- Fiscal strength with significant cash, ongoing revenues and potential milestone payments
- Productive partnerships with top-tier pharmaceutical companies
- Rich product portfolio with multiple drugs in clinical development
- Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.Financially Strong
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver nearly $2 billion in product milestones plus royalties.
Dr Martin Buckland
Dr Stuart Hwang
BIA (UK BioIndustry Association)
Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Mr Alastair Carrington
Dr Karen Chandler-Smith
BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.
Ms Juliette LoweBusiness Development & Membership Services Manager
Ms Lin BatesonExec Director
Dr Alasdair StampsExec Director
Diamond Pharma Services
Diamond Pharma Services is a leading technical and scientific consulting group serving the biotechnology and pharmaceutical industry. Our emphasis is on the following areas:
- Regulatory Affairs: From Product Concept to Registration and Beyond
- Product Development: Nonclinical, CMC and Clinical Aspects
- Pharmacovigilance: Clinical trial (Phase I-IV), Post-Marketing and QPPV Services
- Compliance: GLP, GMP, GCP and QP Services
- Patient Information Leaflet Testing: Over 120 Tested with 100% Positive Agency Feedback
Our clients range from virtual start-up companies to the largest multi-national corporations. Our expertise includes products of recombinant DNA and hybridoma technology, nucleotide based products (RNA and DNA), synthetic peptides, chemical entities (innovative and generic), vaccines (therapeutic and prophylactic), blood products and advanced therapy medicinal products (gene therapy products).
We have sophisticated and well-equipped office facilities and a state-of-the-art IT system. Our IT system includes a fully validated in-house eCTD system (Extedo) and safety database (ARISg). The company was founded in 2005 by Dr. Maureen Graham, formerly Director of Regulatory Affairs at Amgen. Our specialised team of more than 24 professionals includes those with a broad and varied industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.
Mr Paul Cronin
Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.
- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.
The identified protein domains are then used to quickly develop binding/activity assays for use in small molecule hit screening. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging discovery programs. The Domainex services enhance drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.
Dr Eddy Littler
Dr Joanne McCudden
Eden Biodesign is an integrated biopharmaceutical development organisation and part of Watson Pharmaceuticals, Inc. (www.watson.com). Eden Biodesign is designated as Watson’s Centre of Excellence for Biologics, delivering process and product development; cGMP manufacturing and quality/regulatory expertise from a custom-designed facility located in Liverpool, UK.
Mr Kassim Kolia
The Entrepreneurs Fund provides early stage and growth financing alongside active support to entrepreneurial teams. The Entrepreneurs Fund brings the long term perspective, experience and global outlook of a family business in its 5th generation.
Mr Klaas de Boer
Mr Maciek Drozdz
The ERA Consulting Group is one of the longest established and most experienced regulatory affairs and product development consulting groups serving the biopharmaceutical industry.
Our expertise covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective. ERA has the knowledge and experience to assist from conception to registration, and beyond.
ERA has experience with a wide range of products (over 450 to date), including recombinant DNA and hybridoma technology, synthetic peptides, conventional and advanced vaccines, classical blood products, advanced therapy medicinal products comprising gene therapy, somatic cell therapy and tissue-engineered products. ERA also works with innovative new chemical entities, particularly those indicated for neurological, oncological and immunological diseases.
Our specialised international team of more than 30 full-time professionals includes scientists with a research and development background, those with extensive industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.
ERA currently has four office locations (Germany, the UK, the USA and Australia), with the in-house capability to prepare documents and complete submissions on behalf of clients, including a dedicated eCTD group.
Mr. Tristan Elliott
Business Development Manager
Tel: +44(0)20 7510 0200